#weight-loss-drugs

#weight-loss-drugs

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging. At such a critical moment in US history, we need reporters on the ground.

Everyone has heard of the weight loss drug Ozempic. Other brands include Weg­ovy, Mounjaro and Zepbound. These are all basically the same and are based on a natural hormone called GLP-1. Your body makes GLP-1 after a meal and it makes you feel full, stopping you eating.

Lydia* first started thinking about weight-loss drugs during pregnancy. Everyone was talking about them and the advertisements were everywhere, she says, as her baby son naps upstairs. I remember thinking: That's how I'll lose weight for my wedding next year.' When Lydia explains that most of her life before pregnancy was spent in a welter of yo-yo dieting and body dissatisfaction, I say to her that I think most of us can relate.

Figures from the British Association of Aesthetic Plastic Surgeons (Baaps) show facelifts are on the rise in the UK. In 2024 there were 1,882 procedures, up 8% from the previous year. Women accounted for the majority, with numbers rising by 7% to 1,742. But the steepest increase came from men: procedures grew by 26%, from 111 in 2023 to 140 in 2024.

"FDA policymakers have tried to come up with ideas to speed important products to market. ... It is in part directed to achieving some of the (Trump) Administration's goals," said Chad Landmon, chair of Polsenelli's patent and FDA practice.

A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.

In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.

The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration.

Hims & Hers reported a remarkable 111% revenue increase to $586 million, driving its stock up 18%, alongside a 345% net income rise.